4 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
To assess the immunomodulatory effects of erythromycin and clindamycin in healthy volunteers.
To demonstrate that in patients with a CHA2DS2-VASc score of 2 or higher and no history of AF, the use of the Preventicus Heartbeats App increases the detection rate of AF compared to usual care and to demonstrate that AF screening with the app is…